<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095519</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/62461/PMCC</org_study_id>
    <nct_id>NCT05095519</nct_id>
  </id_info>
  <brief_title>Hepatocellular Carcinoma Imaging Using PSMA PET/CT</brief_title>
  <acronym>HepaSMART</acronym>
  <official_title>Hepatocellular Carcinoma Imaging Using PSMA PET/CT - a Prospective Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific&#xD;
      Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis&#xD;
      of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT&#xD;
      (Computed Tomography) or MRI (Magnetic Resonance Imaging).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 patients will be recruited in this prospective pilot study who have HCC on&#xD;
      imaging criteria (LI-RADS 5) for surgical resection, or patients with indeterminate liver&#xD;
      lesions (LI-RADS 3 or 4) planned for liver biopsy. 18F-DCFPYL PSMA PET/CT will be performed&#xD;
      prior to the planned surgery or liver biopsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 4, 2021</start_date>
  <completion_date type="Anticipated">September 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>True Positive Rate per patient</measure>
    <time_frame>6 months</time_frame>
    <description>The probability that HCC is present when the PSMA-PET/CT test result is positive on a per patient basis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>True Negative Rate per patient</measure>
    <time_frame>6 months</time_frame>
    <description>The probability that HCC is absent when the PSMA-PET/CT test result is negative on a per patient basis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>True Positive Rate per lesion</measure>
    <time_frame>6 months</time_frame>
    <description>The probability that HCC is present when the PSMA-PET/CT test result is positive on a per lesion basis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>True Negative Rate per lesion.</measure>
    <time_frame>6 months</time_frame>
    <description>The probability that HCC is absent when the PSMA-PET/CT test result is negative on a per lesion basis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSMA uptake</measure>
    <time_frame>6 months</time_frame>
    <description>Qualitative uptake of PSMA measured on a per lesion basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum standard uptake value</measure>
    <time_frame>6 months</time_frame>
    <description>Maximum standard uptake value of lesions on PSMA PET/CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT LIRADS (Liver Imaging Reporting and Data System) Score</measure>
    <time_frame>6 months</time_frame>
    <description>LI RADS Score for CT lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSMA expression.</measure>
    <time_frame>6 months</time_frame>
    <description>Expression of PSMA per lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLUT-1 expression</measure>
    <time_frame>6 months</time_frame>
    <description>Expression of GLUT 1 per lesion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>18F-DCFPyL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo PET/CT imaging following intravenous administration of 18F-DCFPyL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-DCFPyL</intervention_name>
    <description>18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection</description>
    <arm_group_label>18F-DCFPyL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 years or older at screening&#xD;
&#xD;
          -  Has provided written informed consent for participation in the study&#xD;
&#xD;
          -  Must have risk factors for HCC e.g. cirrhosis, chronic hepatitis B infection with or&#xD;
             without cirrhosis&#xD;
&#xD;
          -  Patients with liver lesions â‰¥1 cm suspicious for HCC but with indeterminate features&#xD;
             on CT and MRI meeting LI-RADS 3 or 4 criteria planned for biopsy, OR patients with&#xD;
             liver lesions diagnostic of HCC based on CT or MRI meeting LI-RADS 5 criteria planned&#xD;
             for surgical resection&#xD;
&#xD;
          -  Patients must be willing and able to comply with the protocol and procedures for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Patients must be available for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abdominal surgery or radiotherapy to the abdomen within &lt;4 weeks of registration.&#xD;
             Patients must have recovered from any effects of any major surgery&#xD;
&#xD;
          -  Uncontrolled intercurrent illness that is likely to impede participation and or&#xD;
             compliance&#xD;
&#xD;
          -  Any history of prostate cancer or elevated PSA level for male patients&#xD;
&#xD;
          -  Other malignancies unless curatively treated with no evidence of disease within&#xD;
             previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in&#xD;
             situ&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product or another&#xD;
             systemic cancer therapy administered in the last 4 weeks&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with requirements of the study&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Cirrhosis due to congenital hepatic fibrosis, vascular disorders (e.g. Budd-Chiari&#xD;
             syndrome) or cardiac cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Grace Kong</last_name>
    <phone>+61 3 85595000</phone>
    <email>NMResearch@petermac.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Research Manager</last_name>
    <phone>+61 3 8559 6602</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Taubman,, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sze Ting Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Kong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Sood, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>PSMA</keyword>
  <keyword>18F-DCFPyL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

